INCY vs PFGC Comparison

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Performance Food Group Co is the third-largest U.S. food-service distributor behind Sysco and us Foods, with 9% market share. PFG's food-service business (52% of 2022 sales) provides customized food products and services (such as product selection and procurement) to independent and chain restaurants, and institutional customers. Acquisitions of Eby-Brown (2019) and Core-Mark (2021) enabled PFG to tap into the convenience store segment (41% of sales), offering convenience products, marketing programs, and technology solutions to convenience stores, drug stores, and other such channels. The firm's Vistar business (7% of sales) is a national distributor of candy, snacks, and beverages to vending and office coffee service distributors, theaters, and hospitality providers.